PDS Biotechnology announces updates data from VERSATILE-002 trial

PDS Biotechnology announced updated data from the VERSATILE-002 trial evaluating Versamune HPV in combination with KEYTRUDA as a first-line treatment for patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma, HNSCC. The data were presented during a poster session on September 14 at the European Society for Medical Oncology, ESMO, Congress 2024 in Barcelona, Spain. The data demonstrated the following: Median Overall Survival was 30 months with a lower 95% confidence interval of 19.7 months; Published mOS for pembrolizumab is 12-18 months; Objective Response Rate of 36%; Published ORR for pembrolizumab is 19-25%; Disease Control Rate is 77%; 21% of patients had deep tumor responses and shrinkage of 90-100% 9% of patients had a complete response; Treatment-related adverse events of Grade greater than or equal to3 were seen in 9 patients